GlassScriptPhysician profile
David J Hartig
NPI 1093797995
$2,700.20
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $504 · 2021: $137 · 2022: $25.31 · 2023: $29.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $261.66 | 2019-2020 | |
| Amgen INC. | $258.64 | 2019-2021 | |
| Novo Nordisk INC | $244.77 | 2019-2020 | |
| Lilly USA, LLC | $207.52 | 2019-2020 | |
| Pfizer INC. | $201.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.47 | 2019-2023 | Tradjenta, Synjardy, Glyxambi |
| Allergan, INC. | $194.37 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.60 | 2019-2020 | |
| Abbvie INC. | $127.79 | 2019-2021 | |
| Astellas Pharma US INC | $109.07 | 2019-2020 | |
| Neos Therapeutics, LP | $105.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $100.93 | 2019-2020 | |
| Amarin Pharma, INC. | $77.98 | 2019 | |
| Merck Sharp & Dohme LLC | $75.28 | 2019 | |
| Arbor Pharmaceuticals, INC. | $58.98 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $40.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $39.36 | 2019 | |
| Sunovion Pharmaceuticals INC. | $37.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.63 | 2019-2020 | |
| Merz North America, INC. | $25.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.14 | 2019 | |
| Therapeuticsmd, INC. | $23.53 | 2019 | |
| Horizon Therapeutics Plc | $18.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.91 | 2019 | |
| Sanofi Pasteur INC. | $17.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.72 | 2020 | |
| Alfasigma USA, INC. | $12.47 | 2020 | |
| Gilead Sciences, INC. | $12.43 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hartig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.